You are here

Content

International Master in Innovative Medicine

In 2016 the Medical Faculty Mannheim launched the first Erasmus Mundus Joint Master (EMJM) of Heidelberg University, the "International Master in Innovative Medicine" (IMIM).

Coordinated and initiated by Rijksuniversiteit Groningen and in cooperation with Universität Heidelberg and Uppsala Universitet, the European Union awarded the programme a grant of over € 2.1 million for the first three cohorts of students and in 2019 additional € 4.4 million for another four cohorts. In 2024, a third round of funding with € 4.6 million for another four cohorts was provided to the IMIM Consortium which was newly joined by Tartu University as additional partner. The EU uses the EMJM label to distinguish high-quality and innovative degree programmes that contribute to the employability of its graduates and foster public-private cooperation. The EU requires that participating universities and partners are international as well as that they provide complementary expertise to strengthen their joint educational offer. Moreover, EMJM programmes are highly selective and students are recruited internationally.

Erasmus Mundus Joint Master

Workshop during the "International Master in Innovative Medicine" at the Medical Faculty Mannheim.

IMIM is a two-year, English-taught master of excellence (M.Sc.), focusing on the education of tomorrow’s leading translational biomedical researchers. Graduates have the skills to apply their knowledge of disease mechanisms to the development of new innovative diagnostic and therapeutic methods. Per year 20 to 25 students study at the interface between research and clinics attending the programme in at least two of the four participating European universities. 

Partner

IMIM is based on Groningen's MSc Molecular Medicine and Innovative Treatment (formerly Medical and Pharmaceutical Drug Innovation), Uppsala’s MMS Molecular Medicine and MMS Medical Research, Tartu’s MSc Bioengineering, and Heidelberg's MSc in Translational Medical Research. In addition, four Latin American Universities – Universidade de São Paulo (Brasil), Pontificia Universidad Católica de Chile (Chile), Universidad de Antioquia (Colombia) and Universidad Nacional Autónoma de México (Mexico) plus Kyoto University and several life science companies participate in the implementation of the Master's degree programme.

Innovation & Industry

An integral part of the curriculum is a course for all students in parallel to the local modules. This “Bench to Bedside and Back” learning line includes several joint annual events with workshops on presentation, communication, team-work and conflict resolution as well as entrepreneurship and innovation, culminating in a research grant or start-up company.

The joint event organized by Heidelberg University is Winter School (formerly Spring School) and includes a conference-style “Innovation Day” (formerly “Industry and Innovation Days”) which is co-organized by the STMM to enable a broad networking and learning experience.

Industry & Innovation Day 2019

Due to its strong focus on innovation and industry the IMIM programme is also supported by EIT Health, an EU-funded network of healthcare companies, public and private research centers, and universities. IMIM students who do at least one industry internship will receive an EIT Health label along with their Master Certificate.

Application

IMIM aims to recruit the best and most motivated students from all over the world with a Bachelor’s degree in biomedical sciences or a related field. A small number of the selected applicants receive a full European EMJMD scholarship.

Application for the IMIM program starts in fall is usually open until mid-January of the respective year. Please find details on:

Context Column

 

PrintImprintPrivacyAccessibility (in German)Easy Language (in German)